1. Indications:

Lenvakin (Lenvatinib) 10 mg is indicated for the treatment of:

• Differentiated thyroid cancer (DTC) that is refractory to radioactive iodine (RAI) therapy.
• Progressive, locally recurrent, or metastatic, radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC).
• Unresectable hepatocellular carcinoma (HCC).

2. Pharmacology:

Lenvakin (Lenvatinib) 10 mg exerts its pharmacological effects by selectively inhibiting multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and platelet-derived growth factor receptors (PDGFR). By blocking these signaling pathways, Lenvakin inhibits angiogenesis (the formation of new blood vessels) and tumor cell proliferation, ultimately leading to tumor regression and inhibition of cancer progression.

3. Dosage and Administration:

The recommended dosage of Lenvakin (Lenvatinib) 10 mg may vary depending on the type of cancer being treated and individual patient characteristics. Typically, the prescribed dose is 10 mg taken orally once daily, with or without food. Treatment should continue until disease progression, unacceptable toxicity, or other treatment discontinuation criteria are met. Dose adjustments or discontinuation may be necessary based on individual patient response and tolerability.

4. Interaction:

Lenvakin (Lenvatinib) 10 mg may interact with other medications, including:

• Strong CYP3A4 inhibitors or inducers: Co-administration with drugs that affect CYP3A4 metabolism may alter the plasma concentration of Lenvakin.
• Acid-reducing agents: Concurrent use of proton pump inhibitors (PPIs) or H2-receptor antagonists may decrease the absorption of Lenvakin, potentially reducing its efficacy.

Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to avoid potential interactions.

5. Side Effects:

Common side effects associated with Lenvakin (Lenvatinib) 10 mg may include:

• Hypertension (high blood pressure)
• Fatigue
• Diarrhea
• Decreased appetite
• Weight loss
• Proteinuria (excess protein in the urine)

Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before using Lenvakin (Lenvatinib) 10 mg, patients should be aware of the following precautions:

• Lenvakin may cause hypertension, which should be monitored and managed appropriately during treatment.
• Proteinuria, including nephrotic syndrome, has been reported with Lenvakin. Urine protein monitoring should be performed before starting treatment and periodically thereafter.
• Hepatotoxicity, including liver function abnormalities, has been reported with Lenvakin. Liver function tests should be performed before starting treatment and periodically thereafter.

7. Overdose Effects:

In case of overdose with Lenvakin (Lenvatinib) 10 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Lenvakin overdose, and patients should seek immediate medical attention if overdose is suspected.